| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9391670 | Journal of Vascular and Interventional Radiology | 2005 | 9 Pages |
Abstract
Patients with HCC who are being considered for treatment with TheraSpheres should be evaluated for the presence of the risk variables described herein. The absence of these variables is predictive of improved survival (median of 466 days) compared with patients at high risk (median of 108 days).
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
James E. PhD, Riad MD, MBA, Brian I. MD, PhD, Janet E. MD, Michael C. MD, Jean-Francois H. MD, Kathleen MS, Mark MS, Kenneth MS,